What is Elevian?
Founded in 2017 and headquartered in Allston, Massachusetts, Elevian is an emerging biotech enterprise dedicated to the development of novel medicines that restore youthful regenerative capacity. The company's core scientific focus lies in identifying and leveraging proteins that can reverse the physiological decline associated with aging. By targeting the root causes of age-related diseases, Elevian aims to provide therapeutic interventions that go beyond symptom management, offering the potential to prevent or treat multiple chronic conditions simultaneously. This focus on regenerative biology places the firm at the intersection of high-growth biotech innovation and the rapidly expanding longevity economy.
How much funding has Elevian raised?
Elevian has raised a total of $55M across 2 funding rounds:
Angel/Seed
$15M
Series A
$40M
Angel/Seed (2020): $15M with participation from Longevity Fund companies, For Good Ventures, Western Technology Investment, Lauder Partners, Kizoo Ventures, SavEarth Fund, Prime Movers Lab, and BOLD Capital Partners
Series A (2021): $40M led by Prime Movers Lab, John A Kuelbs Family Office, Leslie Ventures, and BOLD Capital Group
Key Investors in Elevian
Longevity Fund
A venture capital firm established in 2011, focused on funding companies that develop drugs for age-related diseases and longevity.
Western Technology Investment
Specializes in providing venture debt to assist startups in financing their growth while minimizing shareholder dilution.
Prime Movers Lab
A venture capital firm that focuses on funding breakthrough scientific startups aimed at transforming industries and improving lives.
What's next for Elevian?
With the successful completion of its recent financing round, Elevian is poised to transition into a more intensive phase of clinical development and operational scaling. The strategic allocation of these funds will likely prioritize the advancement of its lead therapeutic candidates through preclinical and early clinical milestones. Furthermore, the company is expected to strengthen its intellectual property portfolio and expand its research team to maintain its competitive edge in the regenerative medicine space. As the firm continues to navigate the complexities of drug development, its ability to demonstrate efficacy in human models will be the primary catalyst for future valuation growth and potential partnerships with larger pharmaceutical entities.
See full Elevian company page
